期刊
CELLS
卷 11, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/cells11081355
关键词
reproductive hormones; calcitonin gene-related peptide; contraception; hormone replacement therapy; ethinylestradiol; efficacy; gender; estradiol; progesterone; regimen
类别
资金
- Boehringer Ingelheim
- Endoceutics
- Merck Sharpe Dohme
- Procter Gamble Co.
- TEVA Women's Health Inc.
- Bayer HealthCare AG, Exceltis, Fidia
- Shionogi Limited
- Theramex
- Abbott
- Allergan
- Eli Lilly
- TEVA
- Teva and lecturing for Allergan
- Amgen
- Teva
- European Commission
- Italian Ministry of Health
- Italian Ministry of University
Migraine is a significant neurological disorder with a major impact on healthcare and socioeconomic systems. Reproductive hormones, especially estrogens, play a crucial role in the pathophysiology of migraine, and prescribing exogenous estrogens may be an effective and safe treatment option for menstrual-related migraine.
Migraine is a major neurological disorder affecting one in nine adults worldwide with a significant impact on health care and socioeconomic systems. Migraine is more prevalent in women than in men, with 17% of all women meeting the diagnostic criteria for migraine. In women, the frequency of migraine attacks shows variations over the menstrual cycle and pregnancy, and the use of combined hormonal contraception (CHC) or hormone replacement therapy (HRT) can unveil or modify migraine disease. In the general population, 18-25% of female migraineurs display a menstrual association of their headache. Here we present an overview on the evidence supporting the role of reproductive hormones, in particular estrogens, in the pathophysiology of migraine. We also analyze the efficacy and safety of prescribing exogenous estrogens as a potential treatment for menstrual-related migraine. Finally, we point to controversial issues and future research areas in the field of reproductive hormones and migraine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据